Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-12.92%
$3.44
0% positive prob.
5-Day Prediction
-13.63%
$3.41
0% positive prob.
20-Day Prediction
-18.22%
$3.23
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | -12.92% | -13.63% | -18.22% | 100.0% | Pending |
| Q2 2026 | BUY | +7.90% | +13.71% | +19.18% | 100.0% | +0.63% |
| Q1 2026 | BUY | +8.94% | +11.90% | +14.05% | 100.0% | +33.58% |
| Q4 2025 | SELL | -13.19% | -12.45% | -16.20% | 100.0% | -22.43% |
SEC 8-K filings with transcript text
Nov 6, 2026 · 100% conf.
1D
-12.92%
$3.44
Act: +21.01%
5D
-13.63%
$3.41
20D
-18.22%
$3.23
2 tmci-ex99_1.htm
Exhibit 99.1
Treace Medical Concepts Reports Third Quarter 2026 Financial Results
Achieved double digit procedure volume growth in the third quarter
PONTE VEDRA, Fla. – November 6, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today reported financial results for the third quarter ended September 30, 2026.
Recent Highlights
• Generated revenue of $48.3 million in the third quarter 2026.
• Improved third quarter 2026 net loss by 23% to $(12.6) million, and Adjusted EBITDA by $2.9 million to $0.3 million when compared to the prior year period.
• Reduced year-to-date cash usage by 53% or $9.7 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $39.8 million as of September 30, 2026.
• Announced 5-Year results of a prospective, multicenter study demonstrating long term, positive outcomes of the Lapiplasty® procedure; a first-in-industry milestone for a commercial instrumented bunion correction system.
• Increased adoption of expanded bunion portfolio with approximately 45% of Lapiplasty® surgeon users now incorporating one or more of the Company’s three new bunion systems launched in the third quarter 2025, up from 40% in the second quarter of 2026.
“We are encouraged by our third quarter performance, reflecting accelerated double-digit case volume growth and continued market share gains – driven by increasing adoption of our comprehensive range of best-in-class bunion systems, as well as our expanding portfolio of new technologies including our SuperBite™ compression screws. These new product offerings are allowing us to penetrate a much broader range of our surgeon customers’ most common foot and ankle procedures,” said John T. Treace, CEO and Chairman of Treace Medical. “We continue to make disciplined investments in key growth initiatives with an emphasis on our product pipeline, while staying focused on improving profitability and reducing cash usage. We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year.”
Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was $48.3 million, representing a decrease of 4% compared to $50.2 million in the third quarter of 2025. The decline was mainly driven by the shift in revenue mix towards lower priced minimally invasive products and lower volume of bunion procedure kits sold. Excluding sales to stocking distributors, bunion kit sales volume increased, and revenue grew mid-single digits compared to third quarter of 2025.
Gross profit for the third quarter of 2026 was $38.4 million compared to $39.7 million in the third quarter of 2025. Gross margin was 79.5% in the third quarter of 2026, compared to 79.1% in the third quarter of 2025.
Total operating expenses decreased $5.5 million, or 10%, to $49.9 million in the third quarter of 2026 compared to total operating expenses of $55.4 million in the third quarter of 2025, primarily driven by targeted expense reduction initiatives across the organization.
Page | 1
Third quarter 2026 net loss decreased by $3.7 million to $(12.6) million, or $(0.19) per share, compared to $(16.3) million, or $(0.26) per share, for the same period in 2025. Adjusted EBITDA increased by $2.9 million to $0.3 million in the third quarter of 2026 compared to $(2.6) million for the same period in 2025. The financial tables and description below provide additional information and a reconciliation of non-GAAP financial information.
Year-to-date cash usage was reduced by 53% or $9.7 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $39.8 million as of September 30, 2026. The Company’s existing credit facility provides up to an additional $115 million of borrowing capacity subject to certain conditions.
2026 Financial Outlook
The Company is updating its full-year 2026 revenue guidance to be in the range of $206 million to $210 million, from the prior range of $204 million to $212 million, representing a decline of 3% to 1% compared to full-year 2025.
The Company is updating its expectation of a loss in Adjusted EBITDA to be in the range of $1.0 million to $2.0 million for full year 2026, from the prior range of $3.0 million to $5.0 million for full year 2026.* The Company reported an Adjusted EBITDA loss of $3.9 million in the full-year 2025.*
The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.
The Company’s full-year 2026 guidance assumes continued case volume growth and improving year-over-year revenue growth rates.
Webcast and Conference Call Details
Treace will host a conference call today, November 6, 2026, at 8:00 a.m. ET
Aug 7, 2026 · 100% conf.
1D
+7.90%
$5.14
Act: -1.89%
5D
+13.71%
$5.41
Act: +0.63%
20D
+19.18%
$5.67
Transcript text not available. View on SEC.gov →
May 8, 2026 · 100% conf.
1D
+8.94%
$2.19
Act: -3.48%
5D
+11.90%
$2.25
Act: +33.58%
20D
+14.05%
$2.29
2 tmci-ex99_1.htm
Exhibit 99.1
Treace Medical Concepts Reports First Quarter 2026 Financial Results
PONTE VEDRA, Fla. – May 8, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026.
Recent Highlights
• Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025.
• Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the first quarter 2026.
• Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, representing an increase of $3.5 million from the Company’s balance of $48.4 million as of December 31, 2025, and compares to an increase of approximately $0.4 million in the first quarter of 2025.
• Initiated limited market release of SuperBite™ Compression Screw System with successful first commercial cases.
• Broadened global patent portfolio surpassing 130 granted patents in addition to over 200 pending patent applications.
“We are encouraged by the growing demand for our comprehensive portfolio of best-in-class bunion and midfoot correction systems, including our new products, which expand our addressable procedure opportunities across our growing surgeon base,” said John T. Treace, CEO and Chairman of Treace Medical. “In the first quarter, we continued to take market share and grow year-over-year case volumes. We remain focused on driving surgeon adoption of our broadened portfolio and commercializing our 2026 new product launches while advancing a robust pipeline of future product innovations. With continued focus on commercial execution and operational discipline, we believe we are well positioned to drive further share gains and return to stronger growth in the back half of the year.”
First Quarter 2026 Financial Results
Revenue for the first quarter of 2026 was $47.2 million, representing a decrease of 10% compared to $52.6 million in the first quarter of 2025.
Gross profit for the first quarter of 2026 was $37.4 million compared to $41.9 million in the first quarter of 2025. Gross margin was 79.3% in the first quarter of 2026, compared to 79.7% in the first quarter of 2025.
Total operating expenses were $54.6 million in the first quarter of 2026 and decreased by $2.9 million compared to total operating expenses of $57.5 million in the first quarter of 2025.
First quarter 2026 net loss was $(18.0) million, or $(0.28) per share, compared to $(15.9) million, or $(0.25) per share, for the same period in 2025. Adjusted EBITDA was $(5.5) million in the first quarter of 2026 compared to $(3.8) million for the same period in 2025. The financial tables and description below provide additional information and a reconciliation of non-GAAP financial information.
Page | 1
Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026. The Company’s existing credit facility provides an additional $115 million of liquidity subject to certain conditions.
2026 Financial Outlook
The Company is reaffirming its full-year 2026 revenue guidance to be in the range of $202 million to $212 million, representing a decline of 5% to 0%, compared to full-year 2025, which was raised in conjunction with its announcement of preliminary operating results on April 9, 2026.
The Company reiterates its expectation of a loss in Adjusted EBITDA in the range of $4.0 million to $6.0 million for full year 2026, as compared to a loss of $3.9 million in the full-year 2025.*
The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.
The Company’s full-year 2026 guidance reflects continued case volume growth, offset by continued headwinds from demand driven product and price mix shift within Treace’s expanded product portfolio.
Webcast and Conference Call Details
Treace will host a conference call today, May 8, 2026, at 8:00 a.m. ET to discuss its first quarter 2026 financial results. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs,
This page provides Treace Medical Concepts Inc. (TMCI) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on TMCI's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.